Key Highlights

  • WWB shares fell 18.53% in today's session to $24.48 from a prior close of $30.04.
  • Windward closed its IPO of 11,838,234 shares at $17.00 per share.
  • Gross proceeds from the IPO and private Placement were about $251.2 million.
  • Sanofi bought $50.0 million of shares and pre-funded warrants in a private placement.

Windward Bio Group (NASDAQ:WWB) shares fell in today's session, days after the clinical-stage biotech began trading on Nasdaq and a day after it announced the closing of its initial public offering. The stock was at $24.48, down 18.53% from the prior close of $30.04, and remains above the $17.00 IPO price. Volume was about 177,000 shares, and the 52-week range runs from $18.35 to $33.99.

Windward is a Basel, Switzerland-based biotech developing ultra-long-acting antibody medicines for serious respiratory and dermatologic diseases, including asthma, COPD and atopic dermatitis. Its shares began trading on the Nasdaq Global Select Market on November 13.

What Did the Offering Raise?

Windward closed its IPO of 11,838,234 common shares at $17.00 per share, which included the full exercise of the underwriters' option to purchase an additional 1,544,117 shares. All of the shares were offered by the company. Gross proceeds from the IPO and the concurrent private placement were approximately $251.2 million. A registration statement for the IPO was declared effective by the SEC on November 12.

What Is Sanofi's Role?

In a concurrent private placement, Sanofi (NASDAQ:SNY) bought 1,532,691 common shares and pre-funded warrants for 1,408,485 common shares, each at the $17.00 IPO price, for an aggregate purchase price of $50.0 million. The shares and warrants were not registered under the Securities Act of 1933.

What Is Windward Developing?

The lead product candidate, WIN378, is a fully human monoclonal antibody designed to inhibit thymic stromal lymphopoietin (TSLP). It is being evaluated in the POLARIS-1 Phase 2/3 study in severe uncontrolled asthma and the SIRIUS Phase 2 study in COPD, and the company has pointed to the potential for twice-yearly dosing.

The second candidate, WIN027, is an ultra-long-acting bispecific antibody targeting TSLP and interleukin-13 and is in a Phase 1 healthy volunteer study. The company estimates the Biologics market it targets at a $60 billion peak.

Clinical Studies Set the Next Checkpoints

Progress in the POLARIS-1 and SIRIUS studies and the WIN027 Phase 1 study are the next points to watch as the company begins life as a public company.